Loading...
•
Jun 30, 2025
IRadimed Q2 2025 Earnings Report
Insperity reported a Q2 net loss driven by higher-than-expected healthcare costs, despite modest revenue growth.
Key Takeaways
Insperity posted a net loss for Q2 2025 due to rising healthcare and benefits costs, which outweighed a slight increase in revenue and paid worksite employees.
Q2 revenue increased 3% year-over-year to $1.658 billion
Net loss of $5 million for the quarter
Adjusted EPS came in at $0.26
Gross profit declined 14% to $223 million due to elevated benefits costs
Revenue by Geographic Location
Forward Guidance
Insperity expects a continued modest increase in worksite employees, but earnings and EBITDA guidance reflect pressure from elevated benefits costs.
Positive Outlook
- Expected Q3 average WSEEs paid to increase 1%–2%
- Adjusted EPS guidance for Q3 between $0.06 and $0.49
- Adjusted EBITDA for Q3 projected between $24M and $44M
- Full year adjusted EPS expected between $1.81 and $2.51
- Full year adjusted EBITDA projected between $170M and $205M
Challenges Ahead
- EPS guidance implies possible net loss in Q3
- Expected continued impact from high healthcare costs
- Net income guidance for Q3 ranges from $(10M) to $7M
- Elevated pharmacy and large claims remain a headwind
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...